Upper gastrointestinal lesions in patients receiving clopidogrel anti-platelet therapy.

[1]  B. Cryer.  Management of patients with high gastrointestinal risk on antiplatelet therapy. , 2009, Gastroenterology clinics of North America.

[2]  U. Marathi,et al.  Clinical trial: comparison of ibuprofen‐phosphatidylcholine and ibuprofen on the gastrointestinal safety and analgesic efficacy in osteoarthritic patients , 2008, Alimentary pharmacology & therapeutics.

[3]  L. Laine,et al.  Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. , 2006, The American journal of medicine.

[4]  K. Chu,et al.  Esomeprazole with aspirin versus clopidogrel for prevention of recurrent gastrointestinal ulcer complications. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[5]  C. Hawkey,et al.  Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin , 2005, Alimentary pharmacology & therapeutics.

[6]  B. Cryer.  Reducing the risks of gastrointestinal bleeding with antiplatelet therapies. , 2005, The New England journal of medicine.

[7]  A. Battler,et al.  Endoscopy in Asymptomatic Minidose Aspirin Consumers , 2005, Digestive Diseases and Sciences.

[8]  B. C. Wong,et al.  High incidence of clopidogrel‐associated gastrointestinal bleeding in patients with previous peptic ulcer disease , 2003, Alimentary pharmacology & therapeutics.

[9]  P. Hsu,et al.  Risk factors for ulcer development in patients with non-ulcer dyspepsia: a prospective two year follow up study of 209 patients , 2002, Gut.

[10]  L. Ignarro,et al.  Platelets modulate gastric ulcer healing: Role of endostatin and vascular endothelial growth factor release , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[11]  M. Feldman,et al.  Time course inhibition of gastric and platelet COX activity by acetylsalicylic acid in humans. , 2000, American journal of physiology. Gastrointestinal and liver physiology.

[12]  E. Toth,et al.  Gastroduodenal tolerance of 75 mg clopidogrel versus 325 mg aspirin in healthy volunteers. A gastroscopic study. , 2000, Scandinavian journal of gastroenterology.

[13]  H. Tseng,et al.  Correlation of serum immunoglobulin G Helicobacter pylori antibody titers with histologic and endoscopic findings in patients with dyspepsia. , 1997, Journal of clinical gastroenterology.

[14]  M. Dennis.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee , 1996 .

[15]  D. Clement.  A randomised, blinded, trial of Clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) , 1996 .

[16]  Walker,et al.  Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients , 1994 .

[17]  Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. , 1994, BMJ.

[18]  R. Corinaldesi,et al.  Helicobacter pylori infection and gastric function in patients with chronic idiopathic dyspepsia. , 1992, Gastroenterology.

[19]  M. Feldman,et al.  Factors Influencing Gastroduodenal Mucosal Prostaglandin Concentrations: Roles of Smoking and Aging , 1992, Annals of Internal Medicine.

[20]  A. Sonnenberg,et al.  Predictors of duodenal ulcer healing and relapse. , 1981, Gastroenterology.